Vimarsana
Biggest News Aggregation in the World

Page 9 - Research Update News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Research Update. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Research Update Today - Breaking & Trending Today

EQS-News: Amoéba (ALMIB): Initiation of coverage - Fighting pathogens, respecting nature - Vimarsana News

EQS-News: Amoéba (ALMIB): Initiation of coverage - Fighting pathogens, respecting nature

EQS-News: / Key word(s): Research Update/Research Update Amoéba (ALMIB): Initiation of coverage - Fighting pathogens, respecting nature 15.03.2023 / 07:00 CET/CEST The issuer is

Cannovum AG share enters Xetra trading - Vimarsana News

Cannovum AG share enters Xetra trading

EQS-News: Cannovum AG / Key word(s): Miscellaneous/Research UpdateCannovum AG share enters Xetra trading 15.12.2022 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 15.12.2022 - The share of Cannovum AG (stock exchanges Frankfurt/Xetra, Düsseldorf, Munich, Hamburg, Berlin...

EQS-News: SphingoTec GmbH: Liberation from renal replacement therapy and early initiation to be supported by the kidney function biomarker Proenkephalin A 119-159 (penKid) - Vimarsana News

EQS-News: SphingoTec GmbH: Liberation from renal replacement therapy and early initiation to be supported by the kidney function biomarker Proenkephalin A 119-159 (penKid)

Issuer: SphingoTec GmbH / Key word(s): Study results/Research Update Liberation from renal replacement therapy and early initiation to be supported by the kidney function biomarker Proenkephalin

Kinarus Therapeutics' KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 - Vimarsana News

Kinarus Therapeutics' KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

Kinarus Therapeutics Holding AG / Key word(s): Research Update Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 06.12.2022 / 07:00 CET/CEST MEDIA RELEASE Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus ...

Kinarus Therapeutics Holding AG: Kinarus Therapeutics' KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 - Vimarsana News

Kinarus Therapeutics Holding AG: Kinarus Therapeutics' KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

Kinarus Therapeutics Holding AG / Key word(s): Research Update Kinarus Therapeutics' KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 06.12.2022